ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes,Pediatric Diabetes

当前位置： X-MOL 学术 › Pediatr. Diabetes › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes
Pediatric Diabetes ( IF 3.4 ) Pub Date : 2022-12-20 , DOI: 10.1111/pedi.13443
Mary B Abraham _{1,

2,

3} , Beate Karges ₄ , Klemen Dovc ₅ , Diana Naranjo ₆ , Ana Maria Arbelaez ₇ , Joyce Mbogo ₈ , Ganesh Javelikar ₉ , Timothy W Jones _{1,

2,

3} , Farid H Mahmud ₁₀

Affiliation

Department of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Australia.
Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, Australia.
Discipline of Pediatrics, Medical School, The University of Western Australia, Perth, Australia.
Division of Endocrinology and Diabetes, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children's Hospital, Ljubljana, Slovenia, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Division of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Division of Endocrinology and Diabetes, Department of Pediatrics, Washington University in St. Louis, St. Louis, Missouri, USA.
Department of Pediatric and Child Health, Aga Khan University Hospital, Nairobi, Kenya.
Department of Endocrinology and Diabetes, Max Super Speciality Hospital, New Delhi, India.
Division of Endocrinology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.

1 WHAT IS NEW OR DIFFERENT?

Updated recommendations of maximum permissible time in hypoglycemia, as defined by continuous glucose monitoring (CGM) metrics as well as details for treatment of hypoglycemia.
Added descriptions of newer easy-to-use formulations of glucagon approved for use, which have variable availability across different regions of the world.
Updated details from studies of newer insulin analogues and technology (CGM and advances in hybrid closed-loop therapy) on reducing the time spent in hypoglycemia.

中文翻译：